Clinical Trial Update: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301 [Phase 3]

View source ↗

Summary

Phase 3 trial Nef-301 evaluating efficacy and safety in Chinese patients with Immunoglobulin A nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Nef-301

Snippet

Sponsor: Everest Medicines (Singapore) Pte. Ltd. | Conditions: Primary Immunoglobulin a Nephropathy (IgAN) | Phase 3 | Status: COMPLETED